FUSN
Income statement / Annual
Last year (2023), Fusion Pharmaceuticals Inc.'s total revenue was $2.07 M,
an increase of 41.55% from the previous year.
In 2023, Fusion Pharmaceuticals Inc.'s net income was -$94.90 M.
See Fusion Pharmaceuticals Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$2.07 M
|
$1.46 M
|
$1.44 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$1.35 M |
$58.90 M |
$56.36 M |
$482,000.00 |
$290,000.00 |
$0.00 |
$0.00 |
| Gross Profit |
$723,000.00 |
-$57.43 M |
-$54.92 M |
-$482,000.00 |
-$290,000.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0.35 |
-39.31 |
-38.14 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$68.76 M
|
$58.90 M
|
$56.36 M
|
$17.19 M
|
$10.63 M
|
$6.88 M
|
$5.37 M
|
| General & Administrative
Expenses |
$31.20 M
|
$30.60 M
|
$27.10 M
|
$20.74 M
|
$7.59 M
|
$3.22 M
|
$1.62 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$31.20 M
|
$30.60 M
|
$27.10 M
|
$20.74 M
|
$7.59 M
|
$3.22 M
|
$1.62 M
|
| Other Expenses |
$762,000.00 |
-$1.78 M |
$469,000.00 |
-$31.72 M |
-$176,000.00 |
-$1.71 M |
$722,000.00 |
| Operating Expenses |
$99.96 M |
$89.50 M |
$83.46 M |
$37.94 M |
$18.04 M |
$9.76 M |
$6.99 M |
| Cost And Expenses |
$101.30 M |
$89.50 M |
$83.46 M |
$37.94 M |
$18.04 M |
$9.76 M |
$6.99 M |
| Interest Income |
$9.53 M |
$2.16 M |
$381,000.00 |
$327,000.00 |
$576,000.00 |
$0.00 |
$0.00 |
| Interest Expense |
$5.17 M |
$1.80 M |
$0.00 |
$327,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$1.35 M
|
$386,000.00
|
$634,000.00
|
$6.88 M
|
$466,000.00
|
$114,000.00
|
$23,000.00
|
| EBITDA |
-$97.89 M
|
-$87.65 M
|
-$81.38 M
|
-$31.05 M
|
-$17.75 M
|
-$9.65 M
|
-$6.96 M
|
| EBITDA Ratio |
-47.33 |
-59.99 |
-56.51 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-47.98
|
-60.26
|
-56.95
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$5.12 M
|
-$1.42 M
|
$850,000.00
|
-$37.79 M
|
$2.28 M
|
-$1.71 M
|
$722,000.00
|
| Income Before Tax |
-$94.11 M |
-$89.45 M |
-$81.17 M |
-$75.72 M |
-$15.94 M |
-$11.47 M |
-$6.26 M |
| Income Before Tax Ratio
|
-45.51
|
-61.22
|
-56.36
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$787,000.00 |
-$1.84 M |
-$118,000.00 |
$2.61 M |
$251,000.00 |
$181,000.00 |
$0.00 |
| Net Income |
-$94.90 M |
-$87.61 M |
-$81.05 M |
-$78.33 M |
-$16.19 M |
-$11.65 M |
-$6.26 M |
| Net Income Ratio |
-45.89 |
-59.97 |
-56.28 |
0 |
0 |
0 |
0 |
| EPS |
-1.45 |
-2 |
-1.9 |
-3.56 |
-0.1 |
-0.62 |
-0.34 |
| EPS Diluted |
-1.45 |
-2 |
-1.9 |
-3.56 |
-0.1 |
-0.62 |
-0.34 |
| Weighted Average Shares
Out |
$65.61 M
|
$43.75 M
|
$42.60 M
|
$22.03 M
|
$155.71 M
|
$18.70 M
|
$18.70 M
|
| Weighted Average Shares
Out Diluted |
$65.61 M
|
$43.75 M
|
$42.60 M
|
$22.03 M
|
$155.71 M
|
$18.70 M
|
$18.70 M
|
| Link |
|
|
|
|
|
|
|
